FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283607> ?p ?o ?g. }

• W4379283607 endingPage "e14524" @default.
• W4379283607 startingPage "e14524" @default.
• W4379283607 abstract "e14524 Background: CAR T-cell therapy has transformed the treatment landscape of B cell malignancies. Adverse effects of CAR T include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). We aimed to identify biomarkers predictive of CRS and ICANS post CAR T-cell therapy. Methods: A total of 34 patients (19 male and 15 female) with a median age of 68 years and ranging from 38 to 80 years old treated with CAR T-cells for B-cell malignancies at Banner University Medical Center/University of Arizona Cancer Center were evaluated. Phosphate (Ph), IL-6, ferritin, lactate dehydrogenase (LDH), and platelet count from each patient were recorded through retrospective chart review. A simple two-sample t test and ANOVA T-test were run to determine statistical significances by comparing the values of each parameter of interest between groups. Results: Of the 34 patients, 19 (56%) developed CRS without ICANS, 8 (24%) had both CRS and ICANS, and 7 (20%) developed neither. Of the 19 patients with CRS without ICANS, 13 (68%) had clinical hypophosphatemia compared to 0% of patients without CRS or CRS+ICANS. Average phosphate (Ph) nadir levels in the patients with CRS were significantly lower at 2.08 mg/dL compared to those in patients without CRS at 3.20 mg/dL ( P= .00007). Patients with CRS + ICANS had even lower Ph levels at 1.99 mg/dL when compared to patients without ( P= .004). Thrombocytopenia at time of infusion was significantly associated with the development of CRS with those patients having an average platelet count of 114 x 10 9 /L compared to 184 x 10 9 /L in patients without CRS or CRS+ICANS (P = .037). Interleukin-6 (IL-6) levels were elevated in all of patients who developed CRS with an average peak level of 102 pg/mL, however, an inadequate number of patients without CRS or CRS+ICANS were sampled thus precluding a statistical comparison in peak IL-6 levels between groups. Conclusions: Hypophosphatemia is associated with the development of both CRS alone and CRS+ICANS after CAR T cell therapy. A proposed mechanism is thought to be related to increased phosphate consumption by CAR T cell induced metabolic activity. Thrombocytopenia at the time of infusion was significantly associated with the development of CRS. Hypophosphatemia and thrombocytopenia show promise as markers for the prediction of CRS and ICANS in CAR T-Cell therapy." @default.
• W4379283607 created "2023-06-05" @default.
• W4379283607 creator A5001408270 @default.
• W4379283607 creator A5008027435 @default.
• W4379283607 creator A5036696622 @default.
• W4379283607 creator A5040597270 @default.
• W4379283607 creator A5053463309 @default.
• W4379283607 creator A5058414763 @default.
• W4379283607 date "2023-06-01" @default.
• W4379283607 modified "2023-10-07" @default.
• W4379283607 title "Hypophosphatemia and thrombocytopenia: A retrospective chart review to identify markers for prediction of CRS and ICANS in CAR T-cell therapy." @default.
• W4379283607 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e14524" @default.
• W4379283607 hasPublicationYear "2023" @default.
• W4379283607 type Work @default.
• W4379283607 citedByCount "0" @default.
• W4379283607 crossrefType "journal-article" @default.
• W4379283607 hasAuthorship W4379283607A5001408270 @default.
• W4379283607 hasAuthorship W4379283607A5008027435 @default.
• W4379283607 hasAuthorship W4379283607A5036696622 @default.
• W4379283607 hasAuthorship W4379283607A5040597270 @default.
• W4379283607 hasAuthorship W4379283607A5053463309 @default.
• W4379283607 hasAuthorship W4379283607A5058414763 @default.
• W4379283607 hasConcept C126322002 @default.
• W4379283607 hasConcept C167135981 @default.
• W4379283607 hasConcept C2778573388 @default.
• W4379283607 hasConcept C71924100 @default.
• W4379283607 hasConcept C90924648 @default.
• W4379283607 hasConceptScore W4379283607C126322002 @default.
• W4379283607 hasConceptScore W4379283607C167135981 @default.
• W4379283607 hasConceptScore W4379283607C2778573388 @default.
• W4379283607 hasConceptScore W4379283607C71924100 @default.
• W4379283607 hasConceptScore W4379283607C90924648 @default.
• W4379283607 hasIssue "16_suppl" @default.
• W4379283607 hasLocation W43792836071 @default.
• W4379283607 hasOpenAccess W4379283607 @default.
• W4379283607 hasPrimaryLocation W43792836071 @default.
• W4379283607 hasRelatedWork W1963989624 @default.
• W4379283607 hasRelatedWork W1972131564 @default.
• W4379283607 hasRelatedWork W2048363928 @default.
• W4379283607 hasRelatedWork W2129462573 @default.
• W4379283607 hasRelatedWork W2164287263 @default.
• W4379283607 hasRelatedWork W2324013405 @default.
• W4379283607 hasRelatedWork W3210359220 @default.
• W4379283607 hasRelatedWork W4229718260 @default.
• W4379283607 hasRelatedWork W4232146933 @default.
• W4379283607 hasRelatedWork W4367672288 @default.
• W4379283607 hasVolume "41" @default.
• W4379283607 isParatext "false" @default.
• W4379283607 isRetracted "false" @default.
• W4379283607 workType "article" @default.